CTOs on the Move

Kensington Retirement Comnty

www.thekensington.org

 
Kensington Retirement Comnty is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

St. Bernard Hospital

St. Bernard Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Chicago, IL. To find more information about St. Bernard Hospital, please visit www.stbh.org

Home Health Care Management Inc.

Home Health Care Management (HHCM) is the parent and management company for our family of home health care providers - Berks Visiting Nurse Association, Visiting Nurse Association of Pottstown and Vicinity, Greater Lehigh Valley Visiting Nurse Association, and Advantage Home Care.

Advanced OandP Solutions

Advanced O&P Solutions is a Hickory Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Leeway Inc

Leeway Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New Haven, CT. To find more information about Leeway Inc, please visit www.leeway.net

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.